Mr Nathan Kuk
Postgraduate student
Centre for Inflammatory Diseases
Human Amniotic Epithelial
Cells, a novel therapy for Inflammatory Bowel Disease
Inflammatory Bowel Disease
(IBD) encompasses a group of idiopathic, chronic and relapsing inflammatory
conditions that affect the gastrointestinal tract, notably Crohn's disease and
Ulcerative Colitis. It is most frequently diagnosed between the ages 15-40 and
as such has life changing effects due to its chronic disabling symptoms. As IBD
is incurable, immunomodulation remains the mainstay therapy with treatments
aimed at maintaining disease remission and preventing flare ups. However
immunomodulation has associated side effects and some patients are refractory
to conventional therapy. Because of this, stem cells have been presented as an
alternative therapeutic option.
Haematopoetic and Mesenchymal
Stem Cells have been studied both in animal models and humans (as part of a
Phase 2 and 3 trial) with variable results. However, human amniotic
epithelial cells (hAECs) have never been transplanted in an IBD model.
Possessing anti-inflammatory and anti-fibrotic properties, hAECs have enormous
potential and as such will be explored in this talk.
Nathan is an MBBS/PhD student currently in his final
year of his PhD. Under the supervision of Professor William Sievert and Drs
Gregory Moore and Alex Hodge, Nathan has
developed a keen interest in gastroenterology, with his experiments involving
human amniotic epithelial cell therapy in models of non-alcoholic fatty liver
disease, acute colitis and chronic colitis. He will be returning to his final
year of medicine in 2018 and endeavours to specialise in
gastroenterology.
A light lunch is served prior to the seminar
at 11:45am in the seminar room foyer, level 2, TRF Building.
Further information, including the link to add the seminar series to your google calendar, is available from CID Weekly Seminar Series website [http://www.med.monash.edu.au/scs/medicine/cid/seminar-series.html]
No comments:
Post a Comment